> Details

Ottema, Sophie; Mulet-Lazaro, Roger; Erpelinck-Verschueren, Claudia; van Herk, Stanley; Havermans, Marije; Arricibita Varea, Andrea; Vermeulen, Michael; Beverloo, H. Berna; Gröschel, Stefan; Haferlach, Torsten; Haferlach, Claudia; J. Wouters, Bas; Bindels, Eric; Smeenk, Leonie; Delwel, Ruud

The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops
  • Contributor: Ottema, Sophie; Mulet-Lazaro, Roger; Erpelinck-Verschueren, Claudia; van Herk, Stanley; Havermans, Marije; Arricibita Varea, Andrea; Vermeulen, Michael; Beverloo, H. Berna; Gröschel, Stefan; Haferlach, Torsten; Haferlach, Claudia; J. Wouters, Bas; Bindels, Eric; Smeenk, Leonie; Delwel, Ruud
  • imprint: Springer Science and Business Media LLC, 2021
  • Published in: Nature Communications
  • Language: English
  • DOI: 10.1038/s41467-021-25862-3
  • ISSN: 2041-1723
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Chromosomal rearrangements are a frequent cause of oncogene deregulation in human malignancies. Overexpression of <jats:italic>EVI1</jats:italic> is found in a subgroup of acute myeloid leukemia (AML) with 3q26 chromosomal rearrangements, which is often therapy resistant. In AMLs harboring a t(3;8)(q26;q24), we observed the translocation of a <jats:italic>MYC</jats:italic> super-enhancer (<jats:italic>MYC</jats:italic> SE) to the <jats:italic>EVI1</jats:italic> locus. We generated an in vitro model mimicking a patient-based t(3;8)(q26;q24) using CRISPR-Cas9 technology and demonstrated hyperactivation of <jats:italic>EVI1</jats:italic> by the hijacked <jats:italic>MYC</jats:italic> SE. This <jats:italic>MYC</jats:italic> SE contains multiple enhancer modules, of which only one recruits transcription factors active in early hematopoiesis. This enhancer module is critical for <jats:italic>EVI1</jats:italic> overexpression as well as enhancer-promoter interaction. Multiple CTCF binding regions in the <jats:italic>MYC</jats:italic> SE facilitate this enhancer-promoter interaction, which also involves a CTCF binding site upstream of the <jats:italic>EVI1</jats:italic> promoter. We hypothesize that this CTCF site acts as an enhancer-docking site in t(3;8) AML. Genomic analyses of other 3q26-rearranged AML patient cells point to a common mechanism by which <jats:italic>EVI1</jats:italic> uses this docking site to hijack enhancers active in early hematopoiesis.</jats:p>
  • Access State: Open Access